Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bidirectional conversion therapy for gastric cancer with peritoneal metastasis
ChiCTR-IIR-17013305Phase 2Not yet recruiting
- Sponsor
- Zhongnan Hospital of Wuhan University
- Start
- Jan 2018
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of Rivoceranib, oxaliplatin, tegafur, gimeracil, oteracil potassium and 2 more in gastric cancer (GC) and peritoneal carcinomatosis (PC) (3 arms), sponsored by Zhongnan Hospital of Wuhan University. Primary endpoints: PCI score differences, Conversion success rate and 1 more. Planned start Jan 2018; status: not yet recruiting.
02
Drugs
Rivoceraniboxaliplatintegafurgimeraciloteracil potassium
03
Conditions
gastric cancer (GC)peritoneal carcinomatosis (PC)
Beyond the preview
Go deeper on ChiCTR-IIR-17013305.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IIR-17013305.